

International Stroke Trial Database

Summary

The IST dataset includes data on 19,435 patients and 112 variables. For each randomised patient, data was extracted on the variables assessed at randomisation, at the early outcome point (14-days after randomisation or prior discharge) and at 6-months and provided as an analysable database. This dataset provides a source of primary data and is available for public use for conduct of secondary analyses and in planning of future trials particularly in older patients and in resource-poor settings given the age distribution of the dataset.

Key Facts

Date Created 2011-11-02

Date Modified 2011-11-02

Version 2

Update Frequency Never

Temporal Coverage 1991 to 1996

Spatial Coverage International

Source Department of Biostatistics, Vanderbilt University; University of

Edinburgh, Department of Clinical Neurosciences

Source License URL http//datashare.is.ed.ac.uk/bitstream/handle/10283/128/license_

text?sequence=12&isAllowed=y

Source License

Requirements

N/A

Source Citation Sandercock, Peter; Niewada, Maciej; Czlonkowska, Anna.

> (2011). International Stroke Trial database (version 2), [dataset]. University of Edinburgh. Department of Clinical Neurosciences.

http//dx.doi.org/10.7488/ds/104.

Keywords Stroke, Clinical trials, RCTs, Randomized Controlled Trials,

> Acute Stroke, Ischaemic Stroke, Haemorrhagic Stroke, Pulmonary embolism, Coronary heart disease, Pneumonia







Other Titles and Uses

- Clinical trial on stroke
- RCT on stroke

Description

The International Stroke Trial (IST) is one of the largest randomised trials ever conducted on individual patients in acute stroke. The IST dataset includes data on 19 435 patients with acute stroke, with 99% complete follow-up. Over 26.4% patients were aged over 80 years at study entry. Background stroke care was limited and none of the patients received thrombolytic therapy.

This clinical trial was conducted between 1991 and 1996 and a pilot phase between 1991 to and 1993. This study is a large, prospective, randomised controlled trial, with 100% complete baseline data and over 99% complete follow-up data. The aim of the trial was to establish whether early administration of aspirin, heparin, both or neither influenced the clinical course of acute ischaemic stroke.



Schema

Field Name	Typ e	Description	Properti es
Hospital_Number	Inte ger	Hospital number	Level: N orminal; Require d
Delay_in_Hours_at_Randomisation	Inte ger	Delay between stroke and randomisation in hours	Level: Ratio
Conscious_State_at_Randomisation	Strin g	Conscious state at randomisation where F - fully alert, D - drowsy, U - unconscious	
Gender	Strin g	Sex where Value: Male, Female	
Age_in_Years	Inte ger	Age in years of subjects	Level: Ratio
Is_Symptoms_Noted_on_Waking	Bool ean	Symptoms noted on waking where	
Is_Atrial_Fibrillation_Coded	Bool ean	Atrial fibrillation; not coded for pilot phase - 984 patients	
Is_CT_Before_Randomisation	Bool ean	CT before randomisation	
Is_Infarct_Visible_on_CT	Bool ean	Infarct visible on CT	
Is_Heparin_Before_Randomisation	Bool ean	Heparin within 24 hours prior to randomisation	
Is_Aspirin_Before_Randomisation	Bool ean	Aspirin within 3 days prior to randomisation	





Field Name	Typ e	Description	Properti es
Systolic_Blood_Pressure_at_Randomisation	Inte ger	Systolic blood pressure at randomisation (mmHg)	Level: Ratio
Face_Deficit	Strin g	Presence or absence of face deficit where Y = True, N = False, C=can't assess	
Arm_Hand_Deficit	Strin g	Presence or absence of arm or hand deficit where Y = True, N = False, C=can't assess	
Leg_Foot_Deficit	Strin g	Presence or absence of leg or foot deficit where Y = True, N = False, C=can't assess	
Dysphasia	Strin g	Presence or absence of dysphasia where Y = True, N = False, C=can't assess	
Hemianopia	Strin g	Presence or absence of hemianopia where Y = True, N = False, C=can't assess	



Field Name	Typ e	Description	Properti es
Visuospatial_Disorder	Strin g	Presence or absence of visuospatial disorder where Y = True, N = False, C=can't assess	
Cerebellar_Signs	Strin g	Presence or absence of brainstem or cerebellar signs where Y = True, N = False, C=can't assess	
Deficit_Others	Strin g	Presence of absence of other deficit where Y = True, N = False, C=can't assess	
Stroke_Subtype	Strin g	Subtype of stroke, either total anterior circulation syndrome (TACS), partial anterior circulation syndrome (PACS), posterior circulation syndrome (POCS) and lacunar syndrome (LACS), and other (OTH)	





Field Name		Тур	Description	Properti
		е		es
Date_of_Randomisation_Oxford		Strin g	Year and month of randomisation done every March 1 from 1991 to 1996; date is in Oxford format (yyyy-mm); date of randomisation per country is coded by country and year (code-yy)	
Local_Time_in_Hours		Inte ger	Local time in hours; (99-missing data) of randomisation dropped	Level: Ordinal
Local_Time_in_Minutes		Inte ger	Local time in minutes; (99-missing data) of randomisation	Level: Ordinal
Local_Day_of_Week		Strin g	Estimate of local day of week (assuming date is Oxford)where 1 - Sunday, 2-Monday, 3-Tuesday, 4-Wednesday, 5-Thursday, 6-Friday,	
Is_Trial_Aspirin_Allocated		Bool ean	Trial aspirin allocated	





Field Name	Typ e	Description	Properti es
Trial_Heparin_Allocated	Strin g	Trial heparin allocated (M/L/N) where M in the main trial is coded as H=high in pilot; where M = high in main trial, H = high in pilot, L = low in main trial and N = avoid heparin; The terminology for the allocated dose of unfractioned heparin changed slightly from the pilot to the main study. Patients were allocated either 12500 units subcutaneously twice daily (coded as H in the pilot and M in the main trial), 5000 units twice daily (coded as L throughout) or to 'avoid heparin' (coded as N throughout).	
Aspirin_Given_For_14_Days	Strin g	Aspirin given for 14 days or till death or discharge where Y = True, N = False, U = Unknown	







Field Name	Typ e	Description	Properti es
Discharged_On_Long_Term_Aspirin	Strin g	Discharged on long term aspirin (Y/N) where Y = True, N = False, U = Unknown	
Low_Dose_Heparin_Given_For_14_Days	Strin g	Low dose heparin given for 14 days or till death/discharge where Y = True, N = False, U = Unknown	
Medium_Dose_Heparin_Given_For_14_Days	Strin g	Medium dose heparin given for 14 days or till death/discharge where Y = True, N = False, U = Unknown	
Is_Medium_Dose_Heparin_Given_For_14_Days_in_Pilot	Bool ean	Medium dose heparin given for 14 days etc in pilot (combine with above)	
Time_In_Days_On_Trial_Treatment	Inte ger	Estimate of time in days on trial treatment	Level: Ordinal
Non_Trial_Subcutaneous_Heparin	Strin g	Non trial subcutaneous heparin (Y/N) where Y = True, N = False, U = Unknown	





Field Name	Тур	Description	Properti es
Non_Trial_Intravenous_Heparin	Strin g	Non trial intravenous heparin where Y = True, N = False, U = Unknown	
Non_Trial_Antiplatelet_Drug	Strin g	Non trial antiplatelet drug where Y = True, N = False, U = Unknown	
Anticoagulants_Others	Strin g	Other anticoagulants given where Y = True, N = False, U = Unknown	
Glycerol_or_Manitol	Strin g	Glycerol or manitol given where Y = True, N = False, U = Unknown	
Steroids	Strin g	Steroids given where Y = True, N = False, U = Unknown	
Calcium_Antagonists	Strin g	Calcium antagonists given where Y = True, N = False, U = Unknown	
Haemodilution	Strin g	Occurence of haemodilution where Y = True, N = False, U = Unknown	





Field Name	Typ e	Description	Properti es
Carotid_Surgery	Strin g	Occurence of carotid surgery where Y = True, N = False, U = Unknown	
Thrombolysis	Strin g	Occurence of thrombolysis where Y = True, N = False, U = Unknown	
Major_Non_Cerebral_Haemorrhage	Strin g	Occurence of major non-cerebral haemorrhage where Y = True, N = False, U = Unknown	
Days_Elapsed_From_Randomisation_to_Major_Non_Cerebral_Hae morrhage	Inte ger	Number of days elapsed from randomization to occurrence of major non cerebral haemorrhage	Level: Ordinal
Comment_on_Major_Non_Cerebral_Haemorrhage	Strin g	Comment on occurrence of major non cerebral haemorrhage	
Side_Effect_Others	Strin g	Occurrence of other side effect where Y = True, N = False, U = Unknown	





Field Name	Typ e	Description	Properti es
Days_Elapsed_From_Randomisation_to_Side_Effects	Inte ger	Number of days elapsed from randomization to occurrence of other side effects	Level: Ordinal
Comment_on_Side_Effect	Strin g	Comment on occurrence of other side effects	
Ischaemic_Stroke	Strin g	Ischaemic stroke as final diagnosis of initial event where Y = True, N = False, U = Unknown	
Haemorrhagic_Stroke	Strin g	Haemorrhagic stroke as final diagnosis of initial event where Y = True, N = False, U = Unknown	
Indeterminate_Stroke	Strin g	Indeterminate stroke as final diagnosis of initial event where Y = True, N = False, U = Unknown	
Not_A_Stroke	Strin g	Not a stroke as final diagnosis of initial event where Y = True, N = False, U = Unknown	
Comment_on_Final_Diagnosis_of_Initial_Event	Strin g	Comment on final diagnosis of initial event	





Field Name	Тур	Description	Properti es
Recurrent_Ischaemic_Stroke	Strin g	Occurrence of ischaemic recurrent stroke within 14 days where Y = True, N = False, U = Unknown	
Days_Elapsed_From_Randomisation_to_Recurrent_Ischaemic_Stroke	Inte ger	Number of days elapsed from randomization to occurrence of recurrent ischaemic stroke	Level: Ordinal
Recurrent_Haemorrhagic_Stroke	Strin g	Occurrence of haemorrhagic stroke within 14 days where Y = True, N = False, U = Unknown	
Days_Elapsed_From_Randomisation_to_Recurrent_Haemorrhagic_ Stroke	Inte ger	Number of days elapsed from randomization to occurrence of haemorrhagic stroke	Level: Ordinal
Unknown_Type	Strin g	Occurrence of unknown type stroke within 14 days where Y = True, N = False, U = Unknown	
Days_Elapsed_From_Randomisation_to_Unknown_Type	Inte ger	Number of days elapsed from randomization to occurrence of unknown type of stroke	Level: Ordinal





Field Name	Typ e	Description	Properti es
Pulmonary_Embolism_Within_14_Days	Strin g	Occurrence of pulmonary embolism within 14 days where Y = True, N = False, U = Unknown	
Days_Elapsed_From_Randomisation_to_Pulmonary_Embolism	Inte ger	Number of days elapsed from randomisation to occurrence of pulmonary embolism within 14 days	Level: Ordinal
Discharged_Alive_From_Hospital_Within_14_Days	Strin g	Discharged alive from hospital within 14 days where Y = True, N = False, U = Unknown	
Days_Elapsed_From_Randomisation_to_Discharged_Alive_From Hospital	n_ Inte ger	Number of days elapsed from randomisation to discharge alive from hospital within 14 days	Level: Ordinal
Discharge_Destination	Strin g	Discharge destination where A = Home, B = Relatives home, C = Residential care, D = Nursing home, E = Other hospital departments and U-Unknown	





Field Name	Тур	Description	Properti
	е		es
Dead_on_Discharge_Within_14_Days	Strin g	Occurrence of death upon discharge where Y = True, N = False, U = Unknown; This death is not necessarily within 14 days of randomisation	
Days_Elapsed_From_Randomisation_to_Dead_on_Discharge	Inte ger	Number of days elapsed from randomisation to dead on discharge where death is not necessarily within 14 days of randomisation	Level: Ordinal
Cause_of_Death_Within_14_Days	Strin g	Cause of death where 1 = Initial stroke, 2 = Recurrent stroke (ischaemic or unknown), 3 = Recurrent stroke (haemorrhagic, 4 = Pneumonia, 5 = Coronary heart disease, 6 = Pulmonary embolism, 7 = Other vascular or unknown, 8 = Non-vascular and 0 = unknown	
Comment_on_Death_Within_14_Days	Strin g	Comment on death within 14 days	





Field Name	Тур	Description	Properti es
Dead_at_Six_Month_Follow_Up	Strin g	Occurrence of death at six month follow-up where Y = True, N = False, U = Unknown	
Days_Elapsed_From_Randomisation_to_Date_of_Last_Contact	Inte ger	Number of days elapsed from randomisation to date of last contact	Level: Ordinal
Days_Elapsed_From_Randomisation_to_Death_at_Six_Month_Follow_Up	Inte ger	Number of days elapsed from randomisation to death at six month follow-up where death is not necessarily within 6 months of randomisation	Level: Ordinal
Cause_of_Death_at_Six_Month_Follow_Up	Strin g	Cause of death where 1 = Initial stroke, 2 = Recurrent stroke (ischaemic or unknown), 3 = Recurrent stroke (haemorrhagic, 4 = Pneumonia, 5 = Coronary heart disease, 6 = Pulmonary embolism, 7 = Other vascular or unknown, 8 = Non-vascular and 0 = unknown	





Field Name	Typ e	Description	Properti es
Comment_on_Death_at_Six_Month_Follow_Up	Strin g	Comment on death at six month follow-up	
Fully_Recovered_at_Six_Month_Follow_Up	Strin g	Fully recovered at six month follow-up where Y = True, N = False, U = Unknown	
Dependent_at_Six_Month_Follow_Up	Strin g	Dependent at six month follow-up where Y = True, N = False, U = Unknown	
Place_of_Residence_at_Six_Month_Follow_Up	Strin g	Place of residence at six month follow-up where A = Home, B = Relatives home, C = Residential care, D = Nursing home, E = Other hospital departments and U = Unknown	
On_Antiplatelet_Drugs_at_Six_Month_Follow_Up	Strin g	On antiplatelet drugs at six month follow-up where Y = True, N = False, U = Unknown	
On_Anticoagulants_at_Six_Month_Follow_Up	Strin g	On anticoagulant at six month follow-up where Y = True, N = False, U = Unknown	





Field Name	Тур	Description	Properti es
Days_Elapsed_From_Randomisation_to_Date_Discharge_Form_ceived	Re Inte ger	Number of days elapsed from randomisation to date discharged form received	Level: Ordinal
Days_Elapsed_From_Randomisation_to_Date_at_Six_Month_Folw_Up_Done	llo Inte ger	Number of days elapsed from randomisation to date at six month follow-up	Level: Ordinal
Abbreviated_Country_Code	Strin g	Abbreviated country code	
Country_Code	Inte ger	Country code	Level: Nominal
Days_Elapsed_From_Randomisation_to_Date_Discharge_Form_mpleted	Co Inte	Number of days elapsed from randomisation to date discharge form completed	Level: Ordinal
Coding_of_Compliance	Strin g	Coding of compliance where provisional categories for non-compliance are the following:	
Is_Compliant_for_Aspirin	Bool ean	Compliance for aspirin	
Is_Compliant_for_Heparin	Bool ean	Compliance for heparin	
Is_Death_Indicator	Bool ean	Indicator for death	
Time_of_Death_in_Days	Inte ger	Time of death or censoring in days	Level: Ordinal





Field Name	Typ e	Description	Properti es
Predicted_Probability_of_Death	Num ber	Predicted probability of death or dependence at 6 month	Level: Ratio
Predicted_Probability_of_Death_at_Six_Month	Num ber	Predicted probability of death at 6 month	Level: Ratio
Predicted_Probability_of_Death_at_14_Days	Num ber	Predicted probability of death at 14 days	Level: Ratio
Is_Dead_or_Alive_at_14_Days	Bool	Known to be dead or alive at 14 days where 1 = yes and 0 = no; this does not necessarily mean that we know outcome at 6 months	
Is_Death_Indicator_at_14_Days	Bool ean	Indicator of death at 14 days	
Six_Month_Outcome	Strin g	Six month outcome where 1 = dead, 2 = dependent, 3 = not recovered, 4 = recovered, 0 or 9 = missing status	
Is_Initial_Stroke_Indicator	Bool ean	Initial stroke as indicator variable for specific cause of death	





Field Name	Typ e	Description	Properti es
Is_Recurrent_Ischaemic_or_Unknown_Stroke_Indicator	Bool ean	Recurrent ischaemic or unknown stroke as indicator variable for specific cause of death	
Is_Recurrent_Haemorrhagic_Stroke_Indicator	Bool ean	Recurrent haemorrhagic stroke as indicator variable for specific cause of death	
Is_Pneumonia_Indicator	Bool ean	Pneumonia as indicator variable for specific cause of death	
Is_Coronary_Heart_Disease_Indicator	Bool ean	Coronary heart disease as indicator variable for specific cause of death	
Is_Pulmonary_Embolism_Indicator	Bool ean	Pulmonary embolism as indicator variable for specific cause of death	
Is_Other_Vascular_Indicator	Bool ean	Other vascular or unknown as indicator variable for specific cause of death	
Is_Non_Vascular_Indicator	Bool ean	Non vascular as indicator variable for specific cause of death	





Field Name	Typ e	Description	Properti es
Is_Haemorrhagic_Stroke_Indicator_Within_14_Days	Bool	Cerebral bleed/h eamorrhagic stroke within 14 days as indicator variable for specific cause of death; this is slightly wider definition than DRSH and is used for analysis of cerebral bleeds	
Is_Ischaemic_Stroke_Indicator_Within_14_Days	Bool ean	Indicator of ischaemic stroke within 14 days	
Is_Indeterminate_Stroke_Indicator_Within_14_Days	Bool ean	Indicator of indeterminate stroke within 14 days	
Is_Any_Stroke_Indicator_Within_14_Days	Bool ean	Indicator of any stroke within 14 days	
Is_Haemorrhagic_Transformation_Indicator_Within_14_Days	Bool ean	Indicator of haemorrhagic transformation within 14 days	
Is_Pulmonary_Embolism_Indicator_Within_14_Days	Bool ean	Indicator of pulmonary embolism within 14 days	
Is_Deep_Vein_Thrombosis_on_Discharge	Bool ean	Indicator of deep vein thrombosis on discharge form	





Field Name	Typ e	Description	Properti es
Is_Major_Non_Cerebral_Bleed_Indicator_Within_14_Days	Bool ean	Indicator of major non-cerebral bleed within 14 days	
Is_Any_Non_Cerebral_Bleed_Indicator_Within_14_Days	Bool ean	Indicator of any non-cerebral bleed within 14 days	

Sample Records

Field Name	Sample 1	Sample 2	Sample 3
Hospital Number	484	1	174
Delay in Hours at Randomisation	28	40	40
Conscious State at Randomisation	Fully Alert	Fully Alert	Fully Alert
Gender	Male	Female	Female
Age in Years	58	87	84
Is Symptoms Noted on Waking	true	false	true
Is Atrial Fibrillation Coded	false	false	false
Is CT Before Randomisation	true	true	false
Is Infarct Visible on CT	true	false	false
Is Heparin Before Randomisation	false	false	false
Is Aspirin Before Randomisation	false	false	false
Systolic Blood Pressure at Randomisation	140	150	190
Face Deficit	no	no	yes
Arm Hand Deficit	yes	yes	yes
Leg Foot Deficit	yes	yes	yes
Dysphasia	no	yes	no
Hemianopia	no	no	no
Visuospatial Disorder	no	no	no





Field Name	Sample 1	Sample 2	Sample 3
Cerebellar Signs	no	no	no
Deficit Others	no	no	no
Stroke Subtype	lacunar syndrome	partial anterior circulation syndrome	lacunar syndrome
Date of Randomisation Oxford	wrz-95	maj-95	lis-93
Local Time in Hours	21	16	16
Local Time in Minutes	34	37	3
Local Day of Week	Wednesday	Monday	Tuesday
Is Trial Aspirin Allocated	false	true	true
Trial Heparin Allocated	avoid heparin	low in main trial	high in main trial
Aspirin Given For 14 Days			
Discharged On Long Term Aspirin			
Low Dose Heparin Given For 14 Days			
Medium Dose Heparin Given For 14 Days			
Is Medium Dose Heparin Given For 14 Days in Pilot			
Time In Days On Trial Treatment	14	14	14
Non Trial Subcutaneous Heparin			
Non Trial Intravenous Heparin			
Non Trial Antiplatelet Drug			
Anticoagulants Others			
Glycerol or Manitol			
Steroids			
Calcium Antagonists			
Haemodilution			
Carotid Surgery			
Thrombolysis			
Major Non Cerebral Haemorrhage			





Field Name	Sample 1	Sample 2	Sample 3
Days Elapsed From Randomisation to Major Non Cerebral Haemorrhage			
Comment on Major Non Cerebral Haemorrhage			
Side Effect Others			
Days Elapsed From Randomisation to Side Effects			
Comment on Side Effect			
Ischaemic Stroke			
Haemorrhagic Stroke			
Indeterminate Stroke			
Not A Stroke			
Comment on Final Diagnosis of Initial Event			
Recurrent Ischaemic Stroke			
Days Elapsed From Randomisation to Recurrent Ischaemic Stroke			
Recurrent Haemorrhagic Stroke			
Days Elapsed From Randomisation to Recurrent Haemorrhagic Stroke			
Unknown Type			
Days Elapsed From Randomisation to Unknown Type			
Pulmonary Embolism Within 14 Days			
Days Elapsed From Randomisation to Pulmonary Embolism			
Discharged Alive From Hospital Within 14 Days			





Field Name	Sample 1	Sample 2	Sample 3
Days Elapsed From Randomisation to Discharged Alive From Hospital			
Discharge Destination			
Dead on Discharge Within 14 Days			
Days Elapsed From Randomisation to Dead on Discharge			
Cause of Death Within 14 Days			
Comment on Death Within 14 Days			
Dead at Six Month Follow Up			yes
Days Elapsed From Randomisation to Date of Last Contact			
Days Elapsed From Randomisation to Death at Six Month Follow Up			57
Cause of Death at Six Month Follow Up			pneumonia
Comment on Death at Six Month Follow Up			
Fully Recovered at Six Month Follow Up			
Dependent at Six Month Follow Up			
Place of Residence at Six Month Follow Up			
On Antiplatelet Drugs at Six Month Follow Up			
On Anticoagulants at Six Month Follow Up			





Field Name	Sample 1	Sample 2	Sample 3
Days Elapsed From Randomisation to Date Discharge Form Received			
Days Elapsed From Randomisation to Date at Six Month Follow Up Done			244
Abbreviated Country Code	ARGE	UK	UK
Country Code	29	27	27
Days Elapsed From Randomisation to Date Discharge Form Completed			
Coding of Compliance			
Is Compliant for Aspirin			
Is Compliant for Heparin			
Is Death Indicator	false	false	true
Time of Death in Days			57
Predicted Probability of Death	0.2412	0.7602	0.7247
Predicted Probability of Death at Six Month	0.0393	0.211	0.1895
Predicted Probability of Death at 14 Days	0.0178	0.0449	0.0425
Is Dead or Alive at 14 Days	'false	'false	true
Is Death Indicator at 14 Days	false	false	false
Six Month Outcome			dead
Is Initial Stroke Indicator	false	false	false
Is Recurrent Ischaemic or Unknown Stroke Indicator	false	false	false
Is Recurrent Haemorrhagic Stroke Indicator	false	false	false
Is Pneumonia Indicator	false	false	true
Is Coronary Heart Disease Indicator	false	false	false
Is Pulmonary Embolism Indicator	false	false	false





Field Name	Sample 1	Sample 2	Sample 3
Is Other Vascular Indicator	false	false	false
Is Non Vascular Indicator	false	false	false
Is Haemorrhagic Stroke Indicator Within 14 Days	false	false	false
Is Ischaemic Stroke Indicator Within 14 Days	false	false	false
Is Indeterminate Stroke Indicator Within 14 Days	false	false	false
Is Any Stroke Indicator Within 14 Days	false	false	false
Is Haemorrhagic Transformation Indicator Within 14 Days	false	false	false
Is Pulmonary Embolism Indicator Within 14 Days	false	false	false
Is Deep Vein Thrombosis on Discharge	false	false	false
Is Major Non Cerebral Bleed Indicator Within 14 Days	false	false	false
Is Any Non Cerebral Bleed Indicator Within 14 Days	false	false	false